



Ref: Syn/CS/SE/BM/2026-27/Apr/05

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 9191
CIN: L85110KA1993PLC014937
www.syngeneintl.com

April 29, 2026

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Sub: Outcome of the Board Meeting

Dear Sir/Madam,

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we wish to inform you that the Board of Directors at its meeting held today (i.e. Wednesday, April 29, 2026) have inter-alia:

Financial Results:

- approved Audited financial results (consolidated and standalone) as per Indian Accounting Standards (Ind-AS) for the quarter and year ended March 31, 2026. A copy of the audited financial results along with the Auditors' Report and a declaration under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed herewith.

Final Dividend:

- recommended a final dividend of Re.1.25/- per Equity Share of Rs. 10/- for the financial year 2025-26. The record date is fixed as Friday, June 26, 2026 for payment of dividend. The dividend will be paid within 30 days from the date of shareholders' approval.

Appointment of Statutory Auditors:

- based on the recommendation of the Audit Committee and subject to the approval of the shareholders, approved the appointment of M/s S. R. Batliboi & Associates LLP, Chartered Accountants (Firm registration number: 101049W/E300004) as the statutory auditors of the Company, for a period of 5 years commencing from the conclusion of the 33rd Annual General Meeting (AGM) of the Company until the AGM to be held in the year 2031. The details as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as **Annexure A**.

Annual General Meeting:

- approved convening of the 33rd Annual General Meeting of the Company on Wednesday, July 29, 2026. Copy of the notice convening the Annual General Meeting will be sent in due course.

Miscellaneous:

- approved the payment of managerial remuneration to Ms. Kiran Mazumdar-Shaw, Executive Chairperson of the Company.



The Board Meeting commenced at 10:00 (IST) and concluded at 16:10 (IST).

The above information will also be made available on the website of the Company at www.syngeneintl.com.

Kindly take the above information on record.

Thanking You

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

Chethan Yogesh
Company Secretary and Compliance Officer

Enclosed:

- Financial results (standalone and consolidated)
- Auditors' Reports (standalone and consolidated)
- Declaration under Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015
- The details required as per Regulation 30 read with Schedule III of the SEBI Listing Regulations and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

SYNGENE INTERNATIONAL LIMITED

CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

(Rs. in million, except per share data)

Sl. No.	Particulars	3 months ended 31 March 2026	Preceding 3 months ended 31 December 2025	Corresponding 3 months ended in the previous year 31 March 2025	Year ended 31 March 2026	Previous year ended 31 March 2025
		(Audited) (Refer Note 3)	(Unaudited)	(Audited) (Refer Note 3)	(Audited)	(Audited)
1	Income					
	a) Revenue from operations	9,600	8,344	9,484	34,238	33,733
	b) Other Income	216	145	184	669	705
	Total Income	9,816	8,489	9,668	34,907	34,438
2	Expenses					
	a) Cost of chemicals, reagents and consumables consumed	2,022	1,979	2,128	8,243	8,683
	b) Changes in inventories of finished goods and work-in-progress	98	85	70	74	171
	c) Employee benefits expense	2,485	2,175	2,094	9,045	8,417
	d) Finance costs	65	62	101	260	312
	e) Depreciation and amortisation expense [refer note 9]	953	971	896	3,871	3,673
	f) Other expenses [refer note 10]	1,925	2,024	2,056	8,087	7,273
	g) Foreign exchange fluctuation loss/ (gain), net	227	234	36	643	13
	Total expenses	7,775	7,530	7,381	30,223	28,542
3	Profit before tax and exceptional items (1-2)	2,041	959	2,287	4,684	5,896
4	Exceptional items, net gain/ (loss) [refer note 6 ,11 & 12]	(74)	(658)	-	(732)	320
5	Profit before tax (3+4)	1,967	301	2,287	3,952	6,216
6	Tax expense					
	Current tax [refer note 7]	337	56	413	681	1,197
	Deferred tax	148	80	130	222	339
	Total tax expense	485	136	543	903	1,536
7	Profit for the period / year (5-6)	1,482	165	1,744	3,049	4,680
8	Other comprehensive income					
	(A) (i) Items that will not be reclassified to profit or loss	11	(25)	64	(53)	28
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(3)	6	(19)	13	(9)
	(B) (i) Items that will be reclassified to profit or loss	(1,340)	46	739	(3,027)	(143)
	(ii) Income tax relating to items that will be reclassified to profit or loss	308	(12)	(187)	752	43
	Other comprehensive income for the period / year, net of taxes	(1,024)	15	597	(2,315)	(81)
9	Total comprehensive income for the period / year (7+8)	458	180	2,341	734	4,599
10	Paid-up equity share capital (Face value of Rs.10 each) [refer note 5]	4,029	4,029	4,025	4,029	4,025
11	Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'				43,009	42,364
12	Earnings per share (of Rs.10 each)	(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)
	a) Basic	3.68	0.41	4.34	7.58	11.64
	b) Diluted	3.68	0.41	4.33	7.57	11.63
	See accompanying notes to the financial results					

SYNGENE INTERNATIONAL LIMITED

CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026						
(Rs. in million, except per share data)						
Sl. No.	Particulars	3 months ended 31 March 2026	Preceding 3 months ended 31 December 2025	Corresponding 3 months ended in the previous year 31 March 2025	Year ended 31 March 2026	Previous year ended 31 March 2025
		(Audited) (Refer Note 3)	(Unaudited)	(Audited) (Refer Note 3)	(Audited)	(Audited)
1	Income					
	a) Revenue from operations	10,365	9,171	10,180	37,387	36,424
	b) Other Income	222	154	189	707	718
	Total Income	10,587	9,325	10,369	38,094	37,142
2	Expenses					
	a) Cost of chemicals, reagents and consumables consumed	2,233	2,209	2,281	9,112	9,254
	b) Changes in inventories of finished goods and work-in-progress	98	85	69	74	171
	c) Employee benefits expense	3,008	2,674	2,530	11,049	9,839
	d) Finance costs	121	119	159	488	531
	e) Depreciation and amortisation expense [refer note 9]	1,115	1,137	1,061	4,529	4,326
	f) Other expenses [refer note 10]	1,781	1,879	1,818	7,358	6,723
	g) Foreign exchange fluctuation loss/ (gain), net	211	232	46	609	19
	Total expenses	8,567	8,335	7,964	33,219	30,863
3	Profit before tax and exceptional items (1-2)	2,020	990	2,405	4,875	6,279
4	Exceptional items, net gain/ (loss) [refer note 6,11 & 12]	(60)	(706)	-	(766)	320
5	Profit before tax (3+4)	1,960	284	2,405	4,109	6,599
6	Tax expense					
	Current tax [refer note 7]	356	109	469	870	1,384
	Deferred tax	125	25	103	72	253
	Total tax expense	481	134	572	942	1,637
7	Profit for the period / year (5-6)	1,479	150	1,833	3,167	4,962
8	Other comprehensive income					
	(A) (i) Items that will not be reclassified to profit or loss	13	(25)	68	(63)	29
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(3)	6	(19)	16	(9)
	(B) (i) Items that will be reclassified to profit or loss	(1,180)	104	697	(2,679)	(211)
	(ii) Income tax relating to items that will be reclassified to profit or loss	313	(14)	(192)	766	44
	Other comprehensive income for the period / year, net of taxes	(857)	71	554	(1,960)	(147)
9	Total comprehensive income for the period / year (7+8)	622	221	2,387	1,207	4,815
10	Paid-up equity share capital (Face value of Rs.10 each) [refer note 5]	4,029	4,029	4,025	4,029	4,025
11	Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'				44,362	43,243
12	Earnings per share (of Rs.10 each)	(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)
	a) Basic	3.68	0.37	4.56	7.87	12.35
	b) Diluted	3.67	0.37	4.56	7.87	12.34
	See accompanying notes to the financial results					

STANDALONE STATEMENT OF ASSETS AND LIABILITIES		
Particulars	(Rs. in Million)	
	As at 31 March 2026	As at 31 March 2025
	(Audited)	(Audited)
ASSETS		
Non-current assets		
Property, plant and equipment [refer note 9]	22,440	19,941
Capital work-in-progress [refer note 8]	5,359	8,754
Right-of-use assets	1,765	1,914
Investment property	315	343
Other intangible assets	350	214
Intangible assets under development	53	47
Financial assets		
(i) Investments	11,189	8,701
(i) Derivative assets	317	1,705
(ii) Other financial assets	2,983	389
Deferred tax assets (net)	842	299
Income tax assets (net)	1,130	1,226
Other non-current assets	123	197
Total non-current assets	46,866	43,730
Current assets		
Inventories	1,369	1,503
Financial assets		
(i) Investments	4,446	5,979
(ii) Trade receivables	4,325	4,694
(iii) Cash and cash equivalents	1,205	2,335
(iv) Bank balances other than (iii) above	6,034	4,190
(v) Derivative assets	69	516
(vi) Other financial assets	304	410
Other current assets	1,010	712
Total current assets	18,762	20,339
Total assets	65,628	64,069
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4,029	4,025
Other equity	43,009	42,364
Total equity	47,038	46,389
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Lease liabilities	1,756	1,785
(ii) Derivative liabilities	488	17
(iii) Other financial liabilities	1	-
Provisions	177	404
Other non-current liabilities	1,979	2,188
Total non-current liabilities	4,401	4,394
Current liabilities		
Financial liabilities		
(i) Borrowings	-	1,025
(ii) Lease liabilities	252	253
(ii) Trade payables		
total outstanding dues of micro and small enterprises	500	295
total outstanding dues of creditors other than micro and small enterprises	2,600	3,170
(iii) Derivative liabilities	1,089	49
(iv) Other financial liabilities	867	630
Provisions	1,005	665
Current tax liabilities (net)	171	40
Other current liabilities	7,705	7,159
Total current liabilities	14,189	13,286
Total equity and liabilities	65,628	64,069

SYNGENE INTERNATIONAL LIMITED
CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra,
Bangalore - 560099

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES		
Particulars	(Rs. in Million)	
	As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment [refer note 9]	25,454	23,226
Capital work-in-progress [refer note 8]	10,404	12,614
Right-of-use assets	3,845	4,192
Investment property	315	343
Other intangible assets	386	256
Intangible assets under development	53	47
Financial assets		
(i) Investments	2,850	362
(ii) Derivative assets	317	1,705
(iii) Other financial assets	3,100	454
Deferred tax assets (net)	1,007	295
Income tax assets (net)	1,267	1,243
Other non-current assets	121	349
Total non-current assets	49,119	45,086
Current assets		
Inventories	1,413	1,555
Financial assets		
(i) Investments	4,561	6,105
(ii) Trade receivables	5,088	5,267
(iii) Cash and cash equivalents	2,286	3,671
(iv) Bank balances other than (iii) above	6,044	4,199
(v) Derivative assets	69	532
(vi) Other financial assets	304	244
Other current assets	1,663	1,300
Total current assets	21,428	22,873
Total assets	70,547	67,959
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4,029	4,025
Other equity	44,362	43,243
Total equity	48,391	47,268
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Lease liabilities	3,985	4,088
(ii) Derivative liabilities	488	18
(iii) Other financial liabilities	1	-
Provisions	180	433
Other non-current liabilities	1,979	2,188
Total non-current liabilities	6,633	6,727
Current liabilities		
Financial liabilities		
(i) Borrowings	94	1,196
(ii) Lease liabilities	505	495
(ii) Trade payables		
total outstanding dues of micro and small enterprises	588	341
total outstanding dues of creditors other than micro and small enterprises	2,887	3,179
(iii) Derivative liabilities	1,145	56
(iv) Other financial liabilities	1,100	704
Provisions	1,144	713
Current tax liabilities (net)	277	84
Other current liabilities	7,783	7,196
Total current liabilities	15,523	13,964
Total equity and liabilities	70,547	67,959

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099

STANDALONE STATEMENT OF CASH FLOWS			
(Rs. in Million)			
Sl. No.	Particulars	Year ended 31 March 2026 (Audited)	Year ended 31 March 2025 (Audited)
1	Cash flows from operating activities		
	Profit for the year	3,049	4,680
	<u>Adjustments to reconcile profit after tax to net cash flows</u>		
	Depreciation and amortisation expense	3,871	3,673
	Gain on remeasurement of lease	-	(32)
	Loss on assets scrapped	28	26
	Provision for doubtful receivables	(53)	57
	Loss on write off of receivables arising from cumulative foreign exchange movements	277	-
	Bad debts written off	2	16
	Provision for doubtful advances to supplier	37	-
	Share based compensation expense	334	302
	Interest expense	260	312
	Unrealised foreign exchange (gain)/loss	58	35
	Net gain on sale of current investments	(90)	(155)
	Interest on income tax refund	(11)	(47)
	Interest income	(568)	(503)
	Provision on inventory obsolescence	131	(23)
	Tax expenses	903	1,536
	Operating profit before working capital changes	8,228	9,877
	Movements in working capital		
	Decrease/ (increase) in inventories	4	861
	Decrease/ (increase) in trade receivables	(202)	(497)
	Decrease/ (increase) in other assets	(1,109)	63
	Increase/ (decrease) in trade payables, other liabilities and provisions	1,831	1,849
	Cash generated from operations	8,752	12,153
	Income taxes paid (net of refunds)	(442)	(1,015)
	Net cash flow generated from operating activities	8,310	11,138
2	Cash flows from investing activities		
	Purchase of property, plant and equipment	(2,638)	(3,693)
	Purchase of intangible assets	(235)	(86)
	Investment in equity shares	(35)	(4,336)
	Investment in bank deposits and inter corporate deposits	(13,828)	(7,965)
	Redemption/ maturity of bank deposits and inter corporate deposits	7,945	8,450
	Interest received	480	498
	Proceeds from sale of current investments	19,198	21,172
	Purchase of current investments	(18,725)	(22,144)
	Net cash flow used in investing activities	(7,838)	(8,104)
3	Cash flows from financing activities		
	Issue of equity shares	4	5
	Proceeds/ (repayments) from long term borrowings	-	(417)
	Proceeds/ (repayments) from short term borrowings, net	(917)	-
	Lease liabilities paid including interest	(268)	(317)
	Dividend paid	(504)	(503)
	Interest paid	(93)	(133)
	Net cash flow used in financing activities	(1,778)	(1,365)
4	Net decrease in cash and cash equivalents (1+2+3)	(1,306)	1,669
5	Effect of exchange difference on cash and cash equivalents held in foreign currency	176	-
6	Cash and cash equivalents at the beginning of the year	2,335	666
7	Cash and cash equivalents at the end of the year (4+5+6)	1,205	2,335

SYNGENE INTERNATIONAL LIMITED

CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099

CONSOLIDATED STATEMENT OF CASH FLOWS			
		(Rs. in Million)	
Sl. No.	Particulars	Year ended	Year ended
		31 March 2026	31 March 2025
		(Audited)	(Audited)
1	Cash flows from operating activities		
	Profit for the year	3,167	4,962
	<u>Adjustments to reconcile profit after tax to net cash flows</u>		
	Depreciation and amortisation expense	4,529	4,326
	Gain on remeasurement of lease	-	(32)
	Loss on assets scrapped	28	26
	Provision for doubtful receivables	(61)	49
	Bad debts written off	2	30
	Loss on write off of receivables arising from cumulative foreign exchange movements	277	-
	Advances to suppliers written off	37	-
	Share based compensation expense	413	373
	Interest expense	488	531
	Unrealised foreign exchange (gain)/loss	37	37
	Net gain on sale of current investments	(94)	(159)
	Interest income	(602)	(512)
	Interest on income tax refund	(11)	(47)
	Provision on inventory obsolescence	112	88
	Tax expenses	942	1,636
	Operating profit before working capital changes	9,264	11,308
	Movements in working capital		
	Decrease/ (increase) in inventories	30	743
	Decrease/ (increase) in trade receivables	(199)	(939)
	Decrease/ (increase) in other assets	(1,461)	(126)
	Increase/ (decrease) in trade payables, other liabilities and provisions	2,211	1,843
	Cash generated from operations	9,845	12,829
	Income taxes paid (net of refunds)	(693)	(1,153)
	Net cash flow generated from operating activities	9,152	11,676
2	Cash flows from investing activities		
	Purchase of property, plant and equipment	(3,440)	(7,603)
	Purchase of intangible assets	(242)	(98)
	Investment in equity shares	(35)	-
	Investment in bank deposits and inter corporate deposits	(13,828)	(12,099)
	Redemption/ maturity of bank deposits and inter corporate deposits	7,945	12,738
	Interest received	508	503
	Proceeds from sale of current investments	21,222	22,547
	Purchase of current investments	(20,734)	(23,435)
	Net cash flow used in investing activities	(8,604)	(7,447)
3	Cash flows from financing activities		
	Proceeds from issue of equity shares	4	5
	Proceeds/(repayments) from long term borrowings	-	(417)
	Proceeds/ (repayments) from short term borrowings, net	(996)	171
	Lease liabilities paid including interest	(548)	(536)
	Dividend paid	(504)	(503)
	Interest paid on borrowings	(106)	(138)
	Net cash flow used in financing activities	(2,150)	(1,418)
4	Net decrease in cash and cash equivalents (1+2+3)	(1,602)	2,811
5	Effect of exchange difference on cash and cash equivalents held in foreign currency	217	3
6	Cash and cash equivalents at the beginning of the year	3,671	857
7	Cash and cash equivalents at the end of the year (4+5+6)	2,286	3,671

SYNGENE INTERNATIONAL LIMITED

Notes :

- 1 The statement of audited standalone and consolidated financial results ("the Statements") of Syngene International Limited ('the Company') for the quarter and year ended 31 March 2026 have been reviewed by the Audit Committee at their meeting held on 28 April 2026 and approved by the Board of Directors of the Company at their meeting held on 29 April 2026. The above Statements have been audited by the statutory auditor of the Company. The reports of the statutory auditor are unqualified. The Statements have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2 The consolidated financial results include the financial results of the Company - Syngene International Limited (including its employee welfare trust) and the financial results of the following subsidiaries:
 - i. Syngene USA Inc.
 - ii. Syngene Scientific Solutions Limited
 - iii. Syngene Manufacturing Solutions LimitedThe Company and the Subsidiaries are collectively referred to as 'the Group'.
- 3 The standalone and consolidated figures for quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures upto end of the third quarter of the relevant financial year which are subjected to limited review.
- 4 The Group operates in a single segment of providing Contract Research and Manufacturing Services.
- 5 On 23 April 2025, the Board of Directors of the Company have approved an allotment of 402,439 equity shares of Rs. 10/- (Rs. Ten each) of the Company to Syngene Employees Welfare Trust at face value pursuant to special resolution passed through Postal Ballot on 23 April 2023 to allot fresh equity shares upto 0.55% (22,00,000 shares) of the paid equity capital of the company in tranches for the purpose of implementation of the Syngene International Limited - Restricted Stock Unit Long Term Incentive Plan FY 2023.
- 6 During the quarter ended 30 June 2024, the Company received its final claim of Rs 320 million from the insurance company for the loss of fixed assets in a fire incident on 12 December 2016, and the same has been presented in the financial results under the head 'Exceptional Items' for the year ended 31 March 2025.
- 7 During the quarter ended 31 December 2024, the Company opted for "Vivad se Vishwas Scheme, 2024" which resulted in settlement of pending TDS assessments related to non resident tax deductions. Consequent to this, tax expense under the scheme amounting to Rs. 95 million was recorded under the head "Current tax" during the year 31 March 2025.
- 8 During the quarter ended 31 March 2025, Syngene USA Inc. (wholly-owned subsidiary of the Company) acquired biologics site in the USA fitted with multiple monoclonal antibody (mAbs) manufacturing lines from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.). This acquisition will increase the company's total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services. This acquisition will also increase the options that can be offered to global customers, providing commercial scale biologics manufacturing capabilities across the Group's global network. The transaction was accounted for as an 'asset acquisition' under Ind AS 103 during the year ended 31 March 2025. The costs incurred till 31 March 2025 eligible for capitalization were accumulated as Capital Work in Progress amounting to Rs. 2,981 million (USD 34.89 million). An amount of Rs. 311 million (USD 3.64 million) was capitalized as Land. These amounts include pre-transaction costs of Rs 101 million (USD 1.18 million). During the year ended 31 March 2026, additional pre-operating cost of Rs. 786 million (USD 8.4 million) eligible for capitalisation is being accumulated under capital work in progress.

SYNGENE INTERNATIONAL LIMITED

- 9 During the quarter ended 30 June 2025, the Company has been granted license for one of the drug substance production line and bonded warehouse license at biologics manufacturing facility, Bangalore, India which was acquired from Stelis Biopharma Limited and was recorded as capital work in progress in earlier years. Consequently, Rs. 3,438 million has been capitalised as property, plant and equipment which has resulted in a higher depreciation of Rs. 70 million and Rs. 247 million during the quarter and period ended 31 March 2026 respectively.
- 10 During the quarter ended 30 September 2025, Rs. 277 million net (Rs. 202 million after tax) was written off as unrecoverable balances in receivables due to cumulative changes in foreign exchange rates.
- 11 On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and Frequently Asked Questions(FAQs) to enable assessment of the financial impact due to changes in regulations. The Group initially assessed and disclosed the incremental impact of these changes on the basis its existing remuneration structure. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group presented such incremental impact under "Exceptional Items" in the standalone and consolidated financial results for the period ended December 31, 2025. The incremental expense consisting of gratuity of Rs. 658 million and Rs. 706 million in the standalone and consolidated financial results respectively primarily arose due to change in wage definition. During the quarter ended 31 March 2026, the management re-assessed the impact of the new labour codes based on the revised remuneration structure. Accordingly, the gratuity obligation was re-measured, resulting in a credit of Rs. 229 million in the standalone financial results and Rs. 244 million in the consolidated financial results for the current quarter. For the year ended 31 March 2026, the net expense recognised under Exceptional Items amounted to Rs. 429 million and Rs. 462 million in the standalone and consolidated financial results, respectively. The Group continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would accordingly take necessary steps for compliance thereof and also provide appropriate accounting effect on the basis of such developments, as needed.
- 12 During the quarter ended 31 March 2026, termination benefits amounting to INR 304 million were extended to employees in accordance with the approved policy. Considering the nature, significance and frequency of these benefits, these are disclosed as "Exceptional items" in the standalone and consolidated financial results.
- 13 **Events after reporting period :**
- a) On 29 April 2026, the Board of Directors of the Company have approved an allotment of 7,29,727 equity shares of Rs. 10/- (Rupees Ten each) of the Company to Syngene Employees Welfare Trust at face value for the purpose of implementation of the Syngene Long Term Incentive Performance Share Plan 2023.
- (b) On 29 April 2026, the Board of Directors recommended a final dividend of Rs. 1.25 per equity share of Rs. 10/-. The proposed dividend is subject to the approval of the shareholders in the Annual General Meeting.

Place :- Bangalore
Date :- 29 April 2026

For and on behalf of the Board of Directors of
Syngene International Limited

KIRAN
MAZUMDAR
SHAW
AR SHAW

Digitally signed
by KIRAN
MAZUMDAR
SHAW
Date: 2026.04.29
15:54:36 +05'30'

Kiran Mazumdar Shaw
Chairperson

Independent Auditor's Report

To the Board of Directors of Syngene International Limited

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Syngene International Limited (hereinafter referred to as the "Company") for the year ended 31 March 2026, attached herewith, (in which are included financial information of its employee welfare trust ('Trust')) being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's and Board of Directors'/Board of Trustees Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the Company/Board of Trustees of the Trust are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company/Trust and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy

Registered Office:

Independent Auditor's Report (Continued)
Syngene International Limited

and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the respective Management and the Board of Directors/Board of Trustees are responsible for assessing the Company's/Trust's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors/Board of Trustees either intends to liquidate the Company/Trust or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors/Board of Trustees are responsible for overseeing the financial reporting process of the Company/Trust.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Independent Auditor's Report (Continued)
Syngene International Limited

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter(s)

- a. The standalone annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

G
PRAKASH
H

Digitally signed
by G PRAKASH
Date: 2026.04.29
16:32:21 +05'30'

G Prakash

Partner

Bengaluru

29 April 2026

Membership No.: 099696

UDIN:26099696AUWAKS3008

Independent Auditor's Report

To the Board of Directors of Syngene International Limited Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Syngene International Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended 31 March 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated annual financial results:

- a. include the annual financial results of the following entities
 1. Syngene International Limited
 2. Syngene USA Inc.
 3. Syngene Scientific Solutions Limited
 4. Syngene Manufacturing Solutions Limited
 5. Syngene Employee Welfare Trust
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Management's and Board of Directors'/Board of Trustees Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

Independent Auditor's Report (Continued)

Syngene International Limited

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies/Trust included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company/Trust and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors/Board of Trustees included in the Group are responsible for assessing the ability of each company/Trust to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors/Board of Trustees either intends to liquidate the Company/Trust or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors/Board of Trustees included in the Group is responsible for overseeing the financial reporting process of each company/Trust.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial

Independent Auditor's Report (Continued)
Syngene International Limited

results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matter(s)

- a. The consolidated annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

G
PRAKASH
Digitally signed
by G PRAKASH
Date: 2026.04.29
16:37:22 +05'30'

G Prakash

Partner

Bengaluru

29 April 2026

Membership No.: 099696

UDIN:26099696HPRRIV1590

Syngene

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.

T +91 80 6891 9191

CIN: L85110KA1993PLC014937

www.syngeneintl.com

April 29, 2026

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

I, Deepak Jain, Chief Financial Officer of Syngene International Limited (CIN: L85110KA1993PLC014937) having its registered office at Biocon Park, Biocon SEZ, Bommasandra Industrial Area, Phase IV, Jigani Link Road, Bengaluru, 560099, India, hereby declare that B S R & Co. LLP, Chartered Accountants (FRN-101248W/W100022), Statutory Auditors of our Company, have issued an Audit Report with unmodified opinion on the audited financial results of the Company (Standalone and Consolidated) for the year ended March 31, 2026.

This declaration is given in compliance to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2016 and SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take the above report on record.

Thanking You,
Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

DEEPA Digitally signed
by DEEPAK JAIN
K JAIN Date: 2026.04.29
18:03:47 +05'30'

Deepak Jain
Chief Financial Officer

Details under Regulation 30 of the SEBI Listing Regulations read along with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sr. No.	Particulars	Details
1.	Reason for change (viz. appointment, re-appointment, resignation, removal, death or otherwise)	Appointment of Statutory Auditors.
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	April 29, 2026 for a term of 5 years commencing from the conclusion of the ensuing 33 rd Annual General Meeting of the Company until the Annual General Meeting to be held in the year 2031
3.	Brief profile	S. R. Batliboi & Associates LLP (“the Firm/SRB”), a limited liability partnership firm incorporated in India, in 1949 with its registered office in Kolkata and has offices across key cities in India. The firm is registered with the Institute of Chartered Accountants of India (“ICAI”) with Firm Registration No. 101049W/E300004. The S.R. Batliboi & Associates network of firms includes - S.R. Batliboi & Co LLP, S.R. Batliboi & Associates LLP, S R B C & CO LLP, S.V. Ghatalia & Associates LLP. All the network firms including the Firm are primarily engaged in providing audit and assurance services to its clients. They along-with its network firms audit several large listed and private companies across diverse market segments including Industrial, Infrastructure, Consumer Products, Financial Services, Technology, Media and Entertainment, Telecommunications and Professional Services.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable